Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

3FF6

Human ACC2 CT domain with CP-640186

Summary for 3FF6
Entry DOI10.2210/pdb3ff6/pdb
Related1od2 1w2x
DescriptorAcetyl-CoA carboxylase 2, (3R)-1'-(9-ANTHRYLCARBONYL)-3-(MORPHOLIN-4-YLCARBONYL)-1,4'-BIPIPERIDINE (3 entities in total)
Functional Keywordsacetyl coa carboxylase, acc2, acc, metabolic disorder, fatty acid metabolism, atp-binding, biotin, fatty acid biosynthesis, ligase, lipid synthesis, manganese, membrane, metal-binding, multifunctional enzyme, nucleotide-binding, phosphoprotein
Biological sourceHomo sapiens (human)
Cellular locationMitochondrion : O00763
Total number of polymer chains4
Total formula weight346508.25
Authors
Williams, S.P.,Madauss, K.P.,Burkhart, W.A. (deposition date: 2008-12-02, release date: 2009-05-19, Last modification date: 2024-04-03)
Primary citationMadauss, K.P.,Burkhart, W.A.,Consler, T.G.,Cowan, D.J.,Gottschalk, W.K.,Miller, A.B.,Short, S.A.,Tran, T.B.,Williams, S.P.
The human ACC2 CT-domain C-terminus is required for full functionality and has a novel twist.
Acta Crystallogr.,Sect.D, 65:449-461, 2009
Cited by
PubMed Abstract: Inhibition of acetyl-CoA carboxylase (ACC) may prevent lipid-induced insulin resistance and type 2 diabetes, making the enzyme an attractive pharmaceutical target. Although the enzyme is highly conserved amongst animals, only the yeast enzyme structure is available for rational drug design. The use of biophysical assays has permitted the identification of a specific C-terminal truncation of the 826-residue human ACC2 carboxyl transferase (CT) domain that is both functionally competent to bind inhibitors and crystallizes in their presence. This C-terminal truncation led to the determination of the human ACC2 CT domain-CP-640186 complex crystal structure, which revealed distinctions from the yeast-enzyme complex. The human ACC2 CT-domain C-terminus is comprised of three intertwined alpha-helices that extend outwards from the enzyme on the opposite side to the ligand-binding site. Differences in the observed inhibitor conformation between the yeast and human structures are caused by differing residues in the binding pocket.
PubMed: 19390150
DOI: 10.1107/S0907444909008014
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (3.19 Å)
Structure validation

227561

PDB entries from 2024-11-20

PDB statisticsPDBj update infoContact PDBjnumon